Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- 1 November 2012
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 13 (11), 1087-1095
- https://doi.org/10.1016/s1470-2045(12)70431-x
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
This publication has 30 references indexed in Scilit:
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibThe New England Journal of Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- The biology of brain metastases—translation to new therapiesNature Reviews Clinical Oncology, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical featuresNeuro-Oncology, 2008
- Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II StudyJournal of Clinical Oncology, 2004